Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients.
Acute kidney injury
Biomarkers
Coronavirus
Creatinine
Kidney
Mortality
Journal
Kidney research and clinical practice
ISSN: 2211-9132
Titre abrégé: Kidney Res Clin Pract
Pays: Korea (South)
ID NLM: 101586778
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
09
2020
accepted:
15
01
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
The prognostic value of within-day sCr variation serum creatinine variation is unknown in the setting of the novel coronavirus disease 2019 (COVID-19). We evaluated the prognostic significance of 24-hour serum creatinine variation in COVID-19 patients. A monocentric retrospective analysis was conducted in COVID-19 patients not admitted to the intensive care unit. Three groups were subdivided based on 24 hours serum creatinine variation from admission. In the stable kidney function group, 24-hour serum creatinine variation ranged from +0.05 to -0.05 mg/dL; in the decreased kidney function group, 24-hour serum creatinine variation was >0.05 mg/dL; in the improved kidney function group, 24-hour serum creatinine variation was <-0.05 mg/dL. The study population included 224 patients with a median age of 66.5 years and a predominance of males (72.3%). Within 24 hours of admission, renal function remained stable in 37.1% of the subjects, whereas it displayed improved and deteriorated patterns in 45.5% and 17.4%, respectively. Patients with decreased kidney function were older and had more severe COVID-19 symptoms than patients with stable or improved kidney function. About half of patients with decreased kidney function developed an episode of acute kidney injury (AKI) during hospitalization. Decreased kidney function was significantly associated with AKI during hospitalization (hazard ratio [HR], 4.6; 95% confidence interval [CI], 1.9-10.8; p < 0.001) and was an independent risk factor for 30-day in-hospital mortality (HR, 5.5; 95% CI, 1.1-28; p = 0.037). COVID-19 patients with decreased kidney function within 24 hours of admission were at high risk of AKI and 30-day in-hospital mortality.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic value of within-day sCr variation serum creatinine variation is unknown in the setting of the novel coronavirus disease 2019 (COVID-19). We evaluated the prognostic significance of 24-hour serum creatinine variation in COVID-19 patients.
METHODS
METHODS
A monocentric retrospective analysis was conducted in COVID-19 patients not admitted to the intensive care unit. Three groups were subdivided based on 24 hours serum creatinine variation from admission. In the stable kidney function group, 24-hour serum creatinine variation ranged from +0.05 to -0.05 mg/dL; in the decreased kidney function group, 24-hour serum creatinine variation was >0.05 mg/dL; in the improved kidney function group, 24-hour serum creatinine variation was <-0.05 mg/dL.
RESULTS
RESULTS
The study population included 224 patients with a median age of 66.5 years and a predominance of males (72.3%). Within 24 hours of admission, renal function remained stable in 37.1% of the subjects, whereas it displayed improved and deteriorated patterns in 45.5% and 17.4%, respectively. Patients with decreased kidney function were older and had more severe COVID-19 symptoms than patients with stable or improved kidney function. About half of patients with decreased kidney function developed an episode of acute kidney injury (AKI) during hospitalization. Decreased kidney function was significantly associated with AKI during hospitalization (hazard ratio [HR], 4.6; 95% confidence interval [CI], 1.9-10.8; p < 0.001) and was an independent risk factor for 30-day in-hospital mortality (HR, 5.5; 95% CI, 1.1-28; p = 0.037).
CONCLUSION
CONCLUSIONS
COVID-19 patients with decreased kidney function within 24 hours of admission were at high risk of AKI and 30-day in-hospital mortality.
Identifiants
pubmed: 34162049
pii: j.krcp.20.177
doi: 10.23876/j.krcp.20.177
pmc: PMC8237119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
231-240Références
Lancet. 2020 Aug 29;396(10251):597-598
pubmed: 32818439
Clin Kidney J. 2020 Jun 06;13(3):354-361
pubmed: 32695326
Kidney Int. 2019 Aug;96(2):429-435
pubmed: 31084924
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Am Soc Nephrol. 2020 Jun;31(6):1157-1165
pubmed: 32345702
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1015-23
pubmed: 24742481
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
J Am Soc Nephrol. 2009 Jun;20(6):1217-21
pubmed: 19389851
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Scand J Clin Lab Invest. 2009;69(8):831-6
pubmed: 19929276
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Sci Rep. 2020 Apr 16;10(1):6552
pubmed: 32300213
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
NDT Plus. 2008 Dec;1(6):392-402
pubmed: 28657002
Am J Nephrol. 2010;31(5):426-34
pubmed: 20389058
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):29-37
pubmed: 27827312
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264